Clicky

Molecular Partners AG(MOLN)

Description: Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.


Keywords: Biopharmaceutical Life Sciences Tumor Clinical Trial Cancer Immunotherapy Acute Myeloid Leukemia Diabetic Macular Edema Molecular Partners Darpin Abicipar Hepatocyte Growth Factor Mp0274

Home Page: www.molecularpartners.com

Wagistrasse 14
Schlieren, 8952
Switzerland
Phone: 41 44 755 77 00


Officers

Name Title
Dr. Patrick Amstutz Ph.D. Co-Founder, CEO, Member of Management Board & Director
Dr. Michael Tobias Stumpp Ph.D. Co-Founder, Exec. VP of Projects & Member of Management Board
Mr. Andreas Emmenegger E.M.B.A. Advisor
Mr. Alexander Zurcher COO & Member of Management Board
Dr. Nicolas Leupin M.B.A., Ph.D., M.D., MBA Chief Medical Officer & Member of Management Board
Ms. Renate Gloggner Exec. VP of People & Community and Member of Management Board
Mr. Daniel Steiner Ph.D. Sr. VP of Research
Mr. Seth D. Lewis Sr. VP of Investor Relations, Communications & Strategy
Mr. Michael Pitzner Gen. Counsel, Compliance Officer & Sr. VP of Legal
Mr. Thomas Schwerzmann VP of HR

Exchange: SW

Country: CH

Currency: Swiss Franc (CHF)

Forward PE: 13.624
Trailing PE: 1.8829
Price-to-Book MRQ: 0.8859
Price-to-Sales TTM: 1.1881
IPO Date:
Fiscal Year End: December
Full Time Employees: 163
Back to stocks